University of Virginia Medical Center Hematology and Medical Oncology

Topics

• Hematopoietic Stem Cell Transplantation 174
• Lymphoma Diagnosis and Treatment 145
• Acute Myeloid Leukemia Research 105
• Chronic Lymphocytic Leukemia Research 99
• Prostate Cancer Treatment and Research 92
• Bladder and Urothelial Cancer Treatments 78
• CAR-T cell therapy research 66
• Cancer Immunotherapy and Biomarkers 56
• Immune Cell Function and Interaction 45
• Renal cell carcinoma treatment 42
• Acute Lymphoblastic Leukemia research 40
• Multiple Myeloma Research and Treatments 39

Most cited

1. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.

   Nature · 2024 · 489 citations · Varinder Kaur

2. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 232 citations · Hall

3. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.

   Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 393 citations · Gentzler

4. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 629 citations · Dillon

5. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation.

   Nature genetics · 2022 · 588 citations · Varinder Kaur

6. Immune checkpoint inhibitor-associated myocarditis: a novel risk score.